Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes.

Annette BauerRaphael WittenbergAmanda LyAnders GustavssonChristin BexeliusClaire TochelMartin KnappMia NelsonCatherine Sudlow

Published in: International journal of technology assessment in health care (2020)

We conclude that in order to ensure that future AD drugs are valued appropriately and timely, early agreement with various stakeholders about outcomes, outcome measures, and cut-offs is important.

Keyphrases

healthcare
public health
mental health
current status
type diabetes
health information
metabolic syndrome
adipose tissue
glycemic control